Related Experiment Video
Updated: Jan 31, 2026

Best Current Practice for Obtaining High Quality EEG Data During Simultaneous fMRI
Published on: June 3, 2013
Concentrated insulins in current clinical practice
Nanette C Schloot1, Robert C Hood2, Sheila M Corrigan3
1Lilly Deutschland GmbH, Werner-Reimers-Str. 2-4, 61352 Bad Homburg, Germany.
Abstract:
New concentrated insulins (exceeding 100 units/mL) and dedicated devices have recently become available, offering new treatment options for people with diabetes, for basal and prandial insulin supplementation. The concentrated insulin formulations range from 2-fold concentration (insulin lispro 200 units/mL) with rapid-acting prandial action to 5-fold concentration (human regular insulin, 500 units/mL) with basal and short-acting prandial actions. Long-acting basal insulins include degludec 200 units/mL and glargine 300 units/mL. Concentrated insulins have been developed with the goal of easing insulin therapy by reducing the volume and number of injections and in some cases making use of altered pharmacokinetic and pharmacodynamic properties. This review summarizes the unique characteristics of each concentrated insulin to help healthcare providers and people with diabetes understand how to best use them.
Related Concept Videos
Concentration Cells
Consider the following voltaic cell:
Insulin Secretory Vesicles
Insulin: The Receptor and Signaling Pathways
Insulin Formulations: Types and Delivery
Short-acting insulins are divided into...
Solution Concentration and Dilution
Stress Concentrations
The stress...

